Abstract
An objective of the present invention is to provide antigen-binding molecules that specifically bind to HER2 mutant. The present invention provides antigen-binding molecules that specifically bind to HER2 mutant, and are capable of modulating and/or activating an immune response; compositions comprising the antigen-binding molecule; and methods of using the same.
Full Text
What is claimed is:
An objective of the present invention is to provide antigen-binding molecules that specifically bind to HER2 mutant. The present invention provides antigen-binding molecules that specifically bind to HER2 mutant, and are capable of modulating and/or activating an immune response; compositions comprising the antigen-binding molecule; and methods of using the same.
Timeline
Filed
05/28/2026Published
09/17/2026Granted
Not AvailableIPC Codes(3)
C07K 16/32:against translation products from oncogenes
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
G01N 33/575:for cancer